Join the 'Extrapyramidal Reaction' group to help and get support from people like you.
Extrapyramidal Reaction News
Related terms: Extrapyramidal Symptoms
FDA Approves Osmolex ER (amantadine) for the treatment of Parkinson’s Disease and Drug-Induced Extrapyramidal Reactions
Posted 22 Feb 2018 by Drugs.com
BRIDGEWATER, N.J., Feb. 19, 2018 (GLOBE NEWSWIRE) – Osmotica Pharmaceutical US LLC (“Osmotica” or the “Company”), a privately-held specialty pharmaceutical company developing novel central nervous system (CNS) treatments utilizing its proprietary osmotic drug delivery platform, announced today that the U.S. Food and Drug Administration (FDA) has approved Osmolex ER, an amantadine extended release ...
Posted 25 Aug 2017 by Drugs.com
EMERYVILLE, Calif., Aug. 24, 2017 (GLOBE NEWSWIRE) – Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced that the U.S. Food and Drug Administration (FDA) has approved Gocovri (amantadine) extended release capsules (previously ADS-5102) for treatment of dyskinesia in patients with Parkinson's disease receiving levodopa-based therapy, with or without concomitant dopaminergic medications. ...
FDA Medwatch Alert: Benztropine Mesylate Injection (Nexus Pharmaceuticals): Recall - Visible Particulate Matter
Posted 5 Aug 2013 by Drugs.com
ISSUE: Nexus Pharmaceuticals Inc. is recalling two lots of Benztropine Mesylate Injection, USP, 2 mg/2mL (1mg/mL) in 2 mL single dose vials due to the presence of visible particulate matter in the vials. The product is manufactured by Allergy Laboratories, Inc. and was distributed by Nexus Pharmaceuticals Inc. Affected product includes Lot Numbers 030712, 112911 The administration of particulate, ...